{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:37:55Z","timestamp":1775147875391,"version":"3.50.1"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Recently, there has been a growing interest in applying immune checkpoint blockers (ICBs), so far used to treat cancer, to patients with bacterial sepsis. We aimed to develop a method for predicting the personal benefit of potential treatments for sepsis, and to apply it to therapy by meropenem, an antibiotic drug, and nivolumab, a programmed cell death-1 (PD-1) pathway inhibitor.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>We defined an optimization problem as a concise framework of treatment aims and formulated a fitness function for grading sepsis treatments according to their success in accomplishing the pre-defined aims. We developed a mathematical model for the interactions between the pathogen, the cellular immune system and the drugs, whose simulations under diverse combined meropenem and nivolumab schedules, and calculation of the fitness function for each schedule served to plot the fitness landscapes for each set of treatments and personal patient parameters.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>Results show that treatment by meropenem and nivolumab has maximum benefit if the interval between the onset of the two drugs does not exceed a dose-dependent threshold, beyond which the benefit drops sharply. However, a second nivolumab application, within 7\u201310 days after the first, can extinguish a pathogen which the first nivolumab application failed to remove. The utility of increasing nivolumab total dose above 6 mg\/kg is contingent on the patient's personal immune attributes, notably, the reinvigoration rate of exhausted CTLs and the overall suppression rates of functional CTLs. A baseline pathogen load, higher than 5,000 CFU\/\u03bcL, precludes successful nivolumab and meropenem combination therapy, whereas when the initial load is lower than 3,000 CFU\/\u03bcL, meropenem monotherapy suffices for removing the pathogen.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold>Our study shows that early administration of nivolumab, 6 mg\/kg, in combination with antibiotics, can alleviate bacterial sepsis in cases where antibiotics alone are insufficient and the initial pathogen load is not too high. The study pinpoints the role of precision medicine in sepsis, suggesting that personalized therapy by ICBs can improve pathogen elimination and dampen immunosuppression. Our results highlight the importance in using reliable markers for classifying patients according to their predicted response and provides a valuable tool in personalizing the drug regimens for patients with sepsis.<\/jats:p>","DOI":"10.3389\/fimmu.2021.616881","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T05:48:40Z","timestamp":1614577720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker"],"prefix":"10.3389","volume":"12","author":[{"given":"Avi","family":"Gillis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Ben Yaacov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zvia","family":"Agur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2017.36","article-title":"The immunopathology of sepsis and potential therapeutic targets","volume":"17","author":"van der Poll","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-31507-8","volume-title":"Precision in Pulmonary, Critical Care, and Sleep Medicine. A clinical and Research Guide","author":"Gomez","year":"2020"},{"key":"B5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.12998\/wjcc.v5.i8.324","article-title":"Treatment of sepsis: What is the antibiotic choice in bacteremia due to carbapenem resistant Enterobacteriaceae?","volume":"5","author":"Alhashem","year":"2017","journal-title":"World J Clin Cases"},{"key":"B6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jac\/dkp139","article-title":"Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution","volume":"64","author":"Roberts","year":"2009","journal-title":"J Antimicrob Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40560-020-00442-7","article-title":"Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial","volume":"8","author":"Lertwattanachai","year":"2020","journal-title":"J Intensive Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/00003088-200544050-00007","article-title":"Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis","volume":"44","author":"Novelli","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1001\/jama.2011.1853","article-title":"The search for effective therapy for sepsis: back to the drawing board?","volume":"306","author":"Angus","year":"2011","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunnol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.3389\/fimmu.2018.02685","article-title":"Sepsis induces a long-lasting state of trained immunity in bone marrow monocytes","volume":"9","author":"Bomans","year":"2018","journal-title":"Frontiers Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B15","first-page":"858","article-title":"Programmed death 1 immune checkpoint inhibitors","volume":"13","author":"Trivedi","year":"2015","journal-title":"Clin Adv Hematol Oncol H&O"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in patients who die of sepsis and multiple organ failure","volume":"306","author":"Boomer","year":"2011","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","article-title":"CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions","volume":"69","author":"Hashimoto","year":"2018","journal-title":"Annu Rev Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1189\/jlb.0110037","article-title":"Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis","volume":"88","author":"Brahmamdam","year":"2010","journal-title":"J Leukocyte Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00134-019-05704-z","article-title":"Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab","volume":"45","author":"Hotchkiss","year":"2019","journal-title":"Intensive Care Med"},{"key":"B20","volume-title":"Highlights of Prescribing Information","year":"2018"},{"key":"B21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/1751143718765407","article-title":"Immune therapy in sepsis: Are we ready to try again?","volume":"19","author":"Davies","year":"2018","journal-title":"J Intensive Care Soci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3390\/ijms18112413","article-title":"Targeting immune cell checkpoints during sepsis","volume":"18","author":"Patil","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S480","DOI":"10.21037\/jtd.2018.01.111","article-title":"Identifying and managing the adverse effects of immune checkpoint blockade","volume":"10","author":"Winer","year":"2018","journal-title":"J Thorac Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B27","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Nivolumab. Updated May 1, 2016","year":"2012"},{"key":"B28","unstructured":"Princeton, NJBristol-Myers Squibb CompanyNivolumab (Opdivo). Highlights of Prescribing Information2014"},{"key":"B29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12967-019-2081-2","article-title":"Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm","volume":"17","author":"Tsur","year":"2019","journal-title":"J Trans Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0226869","DOI":"10.1371\/journal.pone.0226869","article-title":"Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug","volume":"14","author":"Perlstein","year":"2019","journal-title":"PLoS ONE"},{"key":"B31","doi-asserted-by":"publisher","first-page":"504259","DOI":"10.1155\/2015\/504259","article-title":"Mathematical Model of innate and adaptive immunity of sepsis: a modeling and simulation study of infectious disease","volume":"2015","author":"Shi","year":"2015","journal-title":"BioMed Res International"},{"key":"B32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/9781118919408.ch8","article-title":"Mathematical modeling of innate immunity responses of sepsis: modeling and computational studies","volume-title":"Healthcare Analytics: From Data to Knowledge to Healthcare Improvement","author":"Wu","year":"2016"},{"key":"B33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40635-019-0260-3","article-title":"Alleviation of exhaustion-induced immunosuppression and sepsis by immune checkpoint blockers sequentially administered with antibiotics-analysis of a new mathematical model","volume":"7","author":"Gillis","year":"2019","journal-title":"Intensive Care Med Experim"},{"key":"B34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1287\/opre.1060.0320","article-title":"Optimizing chemotherapy scheduling using local search heuristics","volume":"54","author":"Agur","year":"2006","journal-title":"Oper Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"R72","DOI":"10.1186\/cc7881","article-title":"Model for predicting short-term mortality of severe sepsis","volume":"13","author":"Adrie","year":"2009","journal-title":"Crit Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nri3660","article-title":"Emergency granulopoiesis","volume":"14","author":"Manz","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fimmu.2020.00487","article-title":"The role of PD-1 in acute and chronic infection","volume":"11","author":"Jubel","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1172\/JCI82224","article-title":"Sepsis-induced immune dysfunction: can immune therapies reduce mortality?","volume":"126","author":"Delano","year":"2016","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10495-016-1325-3","article-title":"Apoptosis-induced lymphopenia in sepsis and other severe injuries","volume":"22","author":"Girardot","year":"2017","journal-title":"Apoptosis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6766","DOI":"10.4049\/jimmunol.0904054","article-title":"Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism","volume":"184","author":"Unsinger","year":"2010","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discovery"},{"key":"B43","first-page":"192","volume-title":"Elsevier's Integrated Review Immunology and Microbiology","author":"Actor","year":"2012"},{"key":"B44","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.it.2010.05.006","article-title":"Neutrophil kinetics in health and disease","volume":"31","author":"Summers","year":"2010","journal-title":"Trends Immunol"},{"key":"B45","unstructured":"2020"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1182\/blood-2003-10-3448","article-title":"Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness","volume":"103","author":"Muller-Sieburg","year":"2004","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1128\/AAC.48.10.3670-3676.2004","article-title":"Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens","volume":"48","author":"Regoes","year":"2004","journal-title":"Antimicrobial Agents Chemother"},{"key":"B48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12866-016-0823-3","article-title":"Modeling the growth dynamics of multiple Escherichia coli strains in the pig intestine following intramuscular ampicillin treatment","volume":"16","author":"Ahmad","year":"2016","journal-title":"BMC Microbiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1128\/AAC.06486-11","article-title":"In Vivo pharmacokinetics\/pharmacodynamics of colistin and imipenem in pseudomonas aeruginosa biofilm infection","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.diagmicrobio.2010.06.012","article-title":"Comparison of 30-min and 3-h infusion regimens for imipenem\/cilastatin and for meropenem evaluated by Monte Carlo simulation","volume":"68","author":"Lee","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B51","unstructured":"2020"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1128\/AAC.01582-09","article-title":"Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration","volume":"54","author":"Bilgrami","year":"2010","journal-title":"Antimicrobial Agents Chemother"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1473-3099(18)30296-2","article-title":"Quantifying drivers of antibiotic resistance in humans: a systematic review","volume":"18","author":"Chatterjee","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/SHK.0000000000001443","article-title":"Pharmacokinetics, pharmacodynamics and safety of nivolumab in patients with sepsis-induced immunosuppression: a multicenter, open-label phase 1\/2 study","volume":"53","author":"Watanabe","year":"2020","journal-title":"Shock."},{"key":"B55","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5114\/ceji.2015.52835","article-title":"Current views on the mechanisms of immune responses to trauma and infection","volume":"40","author":"Binkowska","year":"2015","journal-title":"Cent Eur J Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jama.2016.2691","article-title":"Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis","volume":"315","author":"van Vught","year":"2016","journal-title":"JAMA"},{"key":"B57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12871-019-0849-9","article-title":"Clinical characteristics, risk factors, immune status and prognosis of secondary infection of sepsis: a retrospective observational study","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Anesthesiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/jcph.600","article-title":"Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients","volume":"56","author":"Kees","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/SHK.0000000000000234","article-title":"Persistent lymphopenia after diagnosis of sepsis predicts mortality","volume":"42","author":"Drewry","year":"2014","journal-title":"Shock"},{"key":"B60","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40425-016-0177-2","article-title":"Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy","volume":"4","author":"Agrawal","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S1473-3099(13)70001-X","article-title":"Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"B62","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/9780470249031.ch36","article-title":"Mathematical Modeling as a New Approach for Improving the Efficacy\/Toxicity Profile of Drugs: The Thrombocytopenia Case Study","volume-title":"Preclinical Development Handbook.","author":"Agur","year":"2008"},{"key":"B63","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/SHK.0000000000000039","article-title":"A perspective on mesenchymal stromal cell transplantation in the treatment of sepsis","volume":"40","author":"Kusadasi","year":"2013","journal-title":"Shock"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.intimp.2013.10.002","article-title":"Depletion of blood neutrophils from patients with sepsis: treatment for the future?","volume":"17","author":"Lewis","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/scd.2008.0143","article-title":"Modeling of asymmetric cell division in hematopoietic stem cells\u2013regulation of self-renewal is essential for efficient repopulation","volume":"18","author":"Marciniak-Czochra","year":"2009","journal-title":"Stem Cells Dev"},{"key":"B66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jtbi.2004.11.026","article-title":"The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model","volume":"234","author":"Vainstein","year":"2005","journal-title":"J Theor Biol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1158\/1078-0432.CCR-18-2564","article-title":"Immune checkpoint inhibitor-induced reinvigoration of tumor-infiltrating CD8(+) T cells is determined by their differentiation status in glioblastoma","volume":"25","author":"Park","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMe1904140","article-title":"Can immune checkpoint inhibitors keep JC virus in check?","volume":"380","author":"Koralnik","year":"2019","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMc1817193","article-title":"Treatment of progressive multifocal leukoencephalopathy with pembrolizumab","volume":"380","author":"Rauer","year":"2019","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3389\/fimmu.2018.02147","article-title":"Epidemiology and immune pathogenesis of viral sepsis","volume":"9","author":"Lin","year":"2018","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.cmi.2018.03.011","article-title":"Towards precision medicine in sepsis: a position paper from the European Society of clinical microbiology and infectious diseases","volume":"24","author":"Rello","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B74","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e1004563","DOI":"10.1371\/journal.ppat.1004563","article-title":"The importance of pathogen load","volume":"11","author":"Cunnington","year":"2015","journal-title":"PLoS Pathog"},{"key":"B76","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","article-title":"Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians","volume":"55","author":"Hryniewicki","year":"2018","journal-title":"J Emerg Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.616881\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T05:27:38Z","timestamp":1697952458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.616881\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2021.616881"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.616881","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]},"article-number":"616881"}}